Genmab A/S (GMAB) Balance Sheet

The dramatic contraction in total assets from $45.8B to $12.5B over six quarters is primarily driven by the $7.2B acquisition outflow in 2025Q4 and the absence of the prior year's milestone cash. Equity has stabilized around $6.0B, but total liabilities have risen to $6.6B, indicating that the balance sheet is now absorbing the revenue shock. This suggests a transition from a cash-rich royalty model to a more capital-intensive commercial phase, with the asset base now more aligned with ongoing operations.

The near-zero leverage in 2025Q2 (D/E of 0.03) has been replaced by a D/E of 0.89 in 2026Q2, with total debt of $5.3B. This is a dramatic shift for a biotech that historically operated with minimal debt, and it appears to be a strategic move to finance the $7.2B acquisition and support the transition to independent commercialization. While the current ratio remains healthy at 2.46, the elevated leverage relative to peers like Regeneron (D/E 0.09) and Incyte (D/E 0.01) introduces refinancing risk and interest expense that could pressure margins if revenue growth does not materialize.

The sharp reduction in goodwill from $2.5B to $355M and PPE from $1.9B to $254M suggests that the 2024Q4 balance sheet included assets from a prior acquisition that have since been impaired or sold. The current asset mix is now dominated by cash and receivables, reflecting a more asset-light model consistent with a royalty-based biotech. However, the increase in debt and the shift toward product sales may require greater investment in manufacturing and commercial infrastructure, which could reverse the asset-light trend.

Despite positive net income in recent quarters, equity growth has been modest, indicating that the company is returning capital to shareholders through buybacks, which totaled $96.4M in 2026Q1 and $405.9M in 2025Q2. This capital deployment, combined with the acquisition, has increased leverage and reduced the equity buffer. The retained earnings growth of $400M over three quarters is less than the cumulative net income, implying that other comprehensive losses or dividends are absorbing part of the earnings.

The cash position has contracted significantly, from $9.9B to $1.5B, largely due to the acquisition outflow and share repurchases. The current ratio of 2.46 remains above the 2.0 threshold, but it is well below the 5.25 level seen in 2024Q4, reflecting a tighter liquidity position. With operating cash flow now around $48M per quarter, the cash runway is limited unless the company can generate higher cash flows from its commercial products or refinance its debt.